Entity

Time filter

Source Type

West Lafayette, IN, United States

Liu J.,University of Cincinnati | Liu J.,Huazhong University of Science and Technology | Guo S.,Kylin Therapeutics Inc. | Cinier M.,University of Cincinnati | And 5 more authors.
ACS Nano | Year: 2011

Both DNA and RNA can serve as powerful building blocks for bottom-up fabrication of nanostructures. A pioneering concept proposed by Ned Seeman 30 years ago has led to an explosion of knowledge in DNA nanotechnology. RNA can be manipulated with simplicity characteristic of DNA, while possessing noncanonical base-pairing, versatile function, and catalytic activity similar to proteins. However, standing in awe of the sensitivity of RNA to RNase degradation has made many scientists flinch away from RNA nanotechnology. Here we report the construction of stable RNA nanoparticles resistant to RNase digestion. The 2'-F (2'-fluoro) RNA retained its property for correct folding in dimer formation, appropriate structure in procapsid binding, and biological activity in gearing the phi29 nanomotor to package viral DNA and producing infectious viral particles. Our results demonstrate that it is practical to produce RNase-resistant, biologically active, and stable RNA for application in nanotechnology. © 2011 American Chemical Society. Source


Abdelmawla S.,Kylin Therapeutics Inc. | Abdelmawla S.,Purdue University | Guo S.,Kylin Therapeutics Inc. | Guo S.,Purdue University | And 7 more authors.
Molecular Therapy | Year: 2011

Previous studies have shown that the packaging RNA (pRNA) of bacteriophage phi29 DNA packaging motor folds into a compact structure, constituting a RNA nanoparticle that can be modularized with functional groups as a nanodelivery system. pRNA nanoparticles can also be self-assembled by the bipartite approach without altering folding property. The present study demonstrated that 2′-F-modified pRNA nanoparticles were readily manufactured through this scalable bipartite strategy, featuring total chemical synthesis and permitting diverse functional modularizations. The RNA nanoparticles were chemically and metabolically stable and demonstrated a favorable pharmacokinetic (PK) profile in mice (half-life (T 1/2): 5-10 hours, clearance (Cl): <0.13l/kg/hour, volume of distribution (V d): 1.2l/kg). It did not induce an interferon (IFN) response nor did it induce cytokine production in mice. Repeat intravenous administrations in mice up to 30mg/kg did not result in any toxicity. Fluorescent folate-pRNA nanoparticles efficiently and specifically bound and internalized to folate receptor (FR +)-bearing cancer cells in vitro. It also specifically and dose-dependently targeted to FR xenograft tumor in mice with minimal accumulation in normal tissues. This first comprehensive pharmacological study suggests that the pRNA nanoparticle had all the preferred pharmacological features to serve as an efficient nanodelivery platform for broad medical applications. © The American Society of Gene & Cell Therapy. Source

Discover hidden collaborations